Cosmo Files Second Patent Suit Against Actavis Over Generic Uceris

Cosmo Technologies filed a second lawsuit against Actavis alleging the drugmaker infringed upon Cosmo’s patent with its newly approved generic for the colitis drug Uceris (budesonide).

The lawsuit, filed in the U.S. District Court for the District of Delaware, was prompted by the FDA’s approval last week of Actavis’ ANDA for a generic for Uceris.

Cosmo previously joined Santarus in suing Actavis over Uceris in 2015, seeking to bar the company from marketing the drug until its patent protection runs out in 2031. Santarus launched Uceris in February 2013.